HBE

ResourceWise (Formerly Prima Markets) Partners with ENGINE for Bio-Bunker Indexes, Now Available on Prima CarbonZero Platform

Retrieved on: 
Thursday, April 4, 2024
Carbon, Database, HBE, Prima, Partnership, RED, Renewable Energy Directive 2018, Biofuel, Traction, Ammonia, Economics, Renewable energy

CHARLOTTE, N.C., April 4, 2024 /PRNewswire/ -- In an inspiring stride towards greener marine operations, ResourceWise and ENGINE have announced a strategic partnership to accelerate the marine industry's decarbonization efforts. With the launch of new bio-bunker benchmarks on the Prima CarbonZero platform, stakeholders in maritime operations now have access to vital data necessary for eco-conscious fuel procurement.   

Key Points: 
  • In Europe, the series indexes bio blends according to whether they are eligible for rebates under the Dutch HBE system.
  • The data series, which is delivered by ResourceWise and ENGINE, is now available on Prima CarbonZero.
  • The low-carbon fuel and feedstocks platform combines pricing and analytics with insightful market commentary and industry deep dives.
  • The platform further addresses the economics of future fuels for shipping, including e-methanol and ammonia.

ResourceWise (Formerly Prima Markets) Partners with ENGINE for Bio-Bunker Indexes, Now Available on Prima CarbonZero Platform

Retrieved on: 
Thursday, April 4, 2024
Carbon, Database, HBE, Prima, Partnership, RED, Renewable Energy Directive 2018, Biofuel, Traction, Ammonia, Economics, Renewable energy

CHARLOTTE, N.C., April 4, 2024 /PRNewswire/ -- In an inspiring stride towards greener marine operations, ResourceWise and ENGINE have announced a strategic partnership to accelerate the marine industry's decarbonization efforts. With the launch of new bio-bunker benchmarks on the Prima CarbonZero platform, stakeholders in maritime operations now have access to vital data necessary for eco-conscious fuel procurement.   

Key Points: 
  • In Europe, the series indexes bio blends according to whether they are eligible for rebates under the Dutch HBE system.
  • The data series, which is delivered by ResourceWise and ENGINE, is now available on Prima CarbonZero.
  • The low-carbon fuel and feedstocks platform combines pricing and analytics with insightful market commentary and industry deep dives.
  • The platform further addresses the economics of future fuels for shipping, including e-methanol and ammonia.

Guild Mortgage Helps Homebuyers Save on Mortgage Payments Through New Payment Advantage Program

Retrieved on: 
Tuesday, December 20, 2022
Finance, Banking, Professional Services, Residential Building & Real Estate, Construction & Property, HBE, History, Mortgage Bankers Association, NYSE, Guild, FHA, Shop, Payment protection insurance, USDA, Freddie Mac, CAP, MBA, Military personnel, Housing, Real estate

Guild Mortgage (NYSE: GHLD), a growth-oriented mortgage lending company originating and servicing residential loans since 1960, introduced Payment Advantage, a new conventional loan program to help homebuyers save on their payments as rates continue to rise.

Key Points: 
  • Guild Mortgage (NYSE: GHLD), a growth-oriented mortgage lending company originating and servicing residential loans since 1960, introduced Payment Advantage, a new conventional loan program to help homebuyers save on their payments as rates continue to rise.
  • Guild’s Payment Advantage program allows homebuyers to lock in a conventional mortgage and Guild will pay 1% of the borrower’s interest rate for one year with a lender paid temporary buydown.
  • After the first year, the borrower will have a predictable payment increase and may be eligible to refinance with Guild through programs such as the Payment Protection program which has no lender fees.
  • Founded in 1960 when the modern U.S. mortgage industry was just forming, Guild Mortgage Company is a nationally recognized independent mortgage lender providing residential mortgage products and local in-house origination and servicing.

Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA

Retrieved on: 
Monday, December 12, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Cystic fibrosis transmembrane conductance regulator, IND, Disease, Exocrine gland, Lung, Partnership, Death, Liver, Pain, Cell, Multimedia, Clinical trial, Annual report, FASN, Beta thalassemia, HBE, Cystic fibrosis, Security (finance), GI, Food, Woman, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vertex Pharmaceuticals, Pancreas, Medication, LNP, Water, VRTX, Therapy, Inhalation, Outline, Degenerative disease, Sickle cell disease, Patient, Research, Biology, Medicine, RNA transfection, Safety, Genotype, Pharmaceutical industry, Vaccine, Biotechnology, Science, Vertex, Innovation district, CFTR, Moderna

Vertex plans to initiate a single ascending dose clinical trial for VX-522 in people with CF in the coming weeks.

Key Points: 
  • Vertex plans to initiate a single ascending dose clinical trial for VX-522 in people with CF in the coming weeks.
  • (Graphic: Business Wire)
    VX-522 is delivered to the lung through inhalation of a CFTR mRNA encapsulated by a lipid nanoparticle.
  • Once delivered to the target lung cells, the mRNA is designed to produce functional copies of the CFTR protein.
  • This investigational messenger ribonucleic acid (mRNA) therapy aims to address the underlying cause of cystic fibrosis (CF).

ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference

Retrieved on: 
Wednesday, May 18, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Inflammation, B cell, RNA transfection, Population, American Thoracic Society, Infection, International Conference on Emerging Infectious Diseases, Patient, Cystic fibrosis, Urinary tract infection, HBE, Cystic fibrosis transmembrane conductance regulator, Therapy, Liver, Â, Cell, Lists of diseases, ATS, Conference, SORT, Mucus, Technology, Recode, CF, LinkedIn, Twitter, LNP, Tissue, Vaccine, CFTR

ReCode Therapeutics , a biopharmaceutical company powering the next wave of genetic medicines through superior delivery, today presented encouraging new preclinical data from the companys inhaled mRNA-based therapeutic program for cystic fibrosis (CF) at the American Thoracic Society (ATS) 2022 International Conference, taking place May 13-18, 2022 in San Francisco.

Key Points: 
  • ReCode Therapeutics , a biopharmaceutical company powering the next wave of genetic medicines through superior delivery, today presented encouraging new preclinical data from the companys inhaled mRNA-based therapeutic program for cystic fibrosis (CF) at the American Thoracic Society (ATS) 2022 International Conference, taking place May 13-18, 2022 in San Francisco.
  • Full details from the preclinical CF data can be accessed via the Presentations section on the companys website.
  • Cystic fibrosis (CF) is a progressive, genetic disease which causes persistent lung infections and respiratory failure.
  • CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and impacts approximately 100,000 people worldwide.

Allego, a Leading Pan-European Public EV Fast Charging Network, Exceeds Revenue and Operational EBITDA Targets for 2021; First Quarter of 2022 Operating Dynamics Remain Robust

Retrieved on: 
Monday, May 16, 2022
Other Transport, Public Transport, Technology, Alternative Vehicles, Fuels, Automotive, General Automotive, Transport, Other Automotive, Electronic Design Automation, Cloud, ICE, Income, Urbanization, Company, Population, EBITDA, City, Bev Facey Community High School, File, Coronavirus, Solution, Contract, COVID-19, Accounting, EVS, EV, HBE, Sale, Carrefour, BEV, Kilowatt-hour, CO2, Growth, NYSE, Annual report, Pharmaceutical industry, Renewable energy, Nissan, EU, European

Charging revenue grew 75% to 26.1 million, driven by higher utilization rates as the fallout from COVID-19 abated and an increased installed base.

Key Points: 
  • Charging revenue grew 75% to 26.1 million, driven by higher utilization rates as the fallout from COVID-19 abated and an increased installed base.
  • In comparison, Allego had about 22,000 public charging ports and approximately 10,800 public and non-public sites at the end of 2020.
  • Importantly, Allegos network delivered 83GWh of clean, 100% renewable energy to EV drivers in 2021, a 77% increase from 2020.
  • Furthermore, with high urbanization rates leading to the scarcity of private charging, the demand for public fast EV charging within Allegos core Europe markets will remain elevated.

ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference

Retrieved on: 
Sunday, May 15, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, RNA transfection, Population, American Thoracic Society, Disease, International Conference on Emerging Infectious Diseases, Primary ciliary dyskinesia, Cystic fibrosis, HBE, Patient, Lipid, Therapy, Liver, Bronchiectasis, Cell, Publication, ATS, Lists of diseases, Conference, SORT, CFTR, Recode, PCD, Lung, Tissue, Vaccine, DNAI1, LNP

Patients with PCD have a high burden of morbidity with chronic respiratory infections, bronchiectasis, and often develop respiratory failure.

Key Points: 
  • Patients with PCD have a high burden of morbidity with chronic respiratory infections, bronchiectasis, and often develop respiratory failure.
  • ReCode is developing a disease-modifying mRNA-based approach for the treatment of PCD caused by mutations in DNAI1, an essential gene for ciliary movement.
  • Full details from the data presented at ATS 2022 can be accessed via the Publications section on ReCodes website.
  • ReCode will also present new preclinical data from its mRNA-based therapeutic program for cystic fibrosis on Wednesday, May 18th.

ReCode Therapeutics Presents Preclinical Data from mRNA-based Cystic Fibrosis Program at 2021 North American Cystic Fibrosis Conference

Retrieved on: 
Wednesday, November 3, 2021
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, HBE, RNA transfection, Primary ciliary dyskinesia, LinkedIn, Cystic fibrosis, CFTR, Twitter, Infection, Patient, Urinary tract infection, Recode, Conference, B cell, Company, Cystic fibrosis transmembrane conductance regulator, CEO, Tissue, Inflammation, IND, Program, Mucus, LNP, Therapy, CF, Liver, Mark (given name), Pharmaceutical industry, Vaccine, Cystic Fibrosis, ReCode Therapeutics, CYSTIC FIBROSIS, RECODE THERAPEUTICS

ReCode Therapeutics , a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, presented new preclinical data today from the Companys inhaled mRNA-based therapeutic program for cystic fibrosis (CF) during an oral poster session at the 2021 North American Cystic Fibrosis Conference (NACFC) .

Key Points: 
  • ReCode Therapeutics , a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, presented new preclinical data today from the Companys inhaled mRNA-based therapeutic program for cystic fibrosis (CF) during an oral poster session at the 2021 North American Cystic Fibrosis Conference (NACFC) .
  • Todays data support the continued development of an inhaled mRNA therapy for the treatment of CF, and we look forward to advancing this program toward an IND submission.
  • ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver.
  • The Companys pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia.

ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

Retrieved on: 
Thursday, October 21, 2021
Professional Services, Health, Genetics, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Series, RNA transfection, HBE, Primary ciliary dyskinesia, Technology, LinkedIn, CFTR, Twitter, DNAI1, Epithelium, Patient, RNA, Recode, B cell, Cystic fibrosis transmembrane conductance regulator, Cystic fibrosis, Company, CEO, Tissue, Cell, PCD, LNP, Therapy, CF, Mouse, Gene editing, Liver, OUP, Pharmaceutical industry, Vaccine

ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.

Key Points: 
  • ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
  • Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, L.P., and Osage University Partners (OUP).
  • Oleg Nodelman, founder and portfolio manager of EcoR1 Capital also joined ReCodes Board of Directors in connection with the financing.
  • ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver.

ReCode Therapeutics Presents Encouraging Preclinical Data from Inhaled mRNA Therapeutics Program in Primary Ciliary Dyskinesia at the 2021 PCD on the Move Virtual Scientific Conference

Retrieved on: 
Thursday, August 5, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Company, Chief executive officer, Primary ciliary dyskinesia, PCD, B cell, Tissue, Axoneme, Conference, Program, Therapy, Patient, Twitter, MCC, Quality of life, Gene, Mucociliary clearance, Recode, HBE, Degenerative disease, RNA transfection, Cystic fibrosis, Liver, Mucus, Cell, LinkedIn, Death, Disease, Vaccine, Primary Ciliary Dyskinesia (PCD), ReCode Therapeutics, PRIMARY CILIARY DYSKINESIA (PCD), RECODE THERAPEUTICS

The data featured today demonstrate that delivery of our LNP-formulated mRNA leads to production of DNAI1 protein in the target cells and rescue of ciliary function.

Key Points: 
  • The data featured today demonstrate that delivery of our LNP-formulated mRNA leads to production of DNAI1 protein in the target cells and rescue of ciliary function.
  • ReCode Therapeutics is developing an mRNA-based therapy for the treatment of PCD caused by mutations in DNAI1.
  • Primary ciliary dyskinesia (PCD) is a disease characterized by deficient mucociliary clearance (MCC), chronic respiratory tract infections and premature death.
  • The Companys pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia.